Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464437 · ClinicalTrials.gov registry record · Phase 2
AMG 151 Amgen Protocol Number 20100761
A Phase 2 study of Diabetes Mellitus, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 236
- Enrollment target
- 20
- Study locations
NCT01464437: Completed Phase 2 study of Diabetes Mellitus, sponsored by Amgen.
NCT01464437 is a Phase 2 study of Diabetes Mellitus that has completed, run by Amgen. The registered enrollment target is 236 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01464437, a Phase 2 study of Diabetes Mellitus, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 236 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group, fixed dose study. AMG 151 will be evaluated in subjects with type 2 diabetes treated with metformin for at least 3 months prior to randomization.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG AMG 151
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Chula Vista
- Research Site - Fresno
- Research Site - Greenbrae
- Research Site - Inglewood
- Research Site - Lomita
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Palm Desert
- Research Site - Roseville
- Research Site - San Diego
- Research Site - San Jose
- Research Site - Walnut Creek
- Research Site - Watsonville
Arizona
- Research Site - Phoenix
- Research Site - Tucson
Florida
- Research Site - Bradenton
- Research Site - Brooksville
Alabama
- Research Site - Birmingham
Arkansas
- Research Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01464437 record still lists
NCT01464437 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01464437 names 20 study sites across 5 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01464437 about?
NCT01464437 is a clinical study titled "AMG 151 Amgen Protocol Number 20100761". This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group, fixed dose study. AMG 151 will be evaluated in subjects with type 2 diabetes treated with metformin for at least 3 months prior to randomization.
What is the current status of trial NCT01464437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2011-09. Estimated completion is 2012-12.
What conditions does trial NCT01464437 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT01464437?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), AMG 151 (DRUG).
Who is sponsoring clinical trial NCT01464437?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01464437 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01464437's enrollment target sits among peer trials
236 85th of 208 higher than 124 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
RECRUITING · Phase 2
-
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia